Kiniksa Pharmaceuticals International, plc KNSA
75.08
(0.26)
(0.35%)
as of 25 Sep
- Market cap
- $5.9B
- P/E
- 70.2×
Follow KNSA
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
| ROE |
+8 more TTM periods Free account |
7.39% | 11.73% | 13.74% | 14.04% |
| ROA | 5.67% | 8.78% | 10.26% | 10.36% | |
| ROIC | 13.01% | 31.44% | 42.34% | 48.87% | |
| Return on Tangible Assets | 10.16% | 15.13% | 16.62% | 16.13% | |
| Average Days of Receivables | 31.58 | 8.40 | 11.24 | 10.20 | |
| Free Cash Flow per Share | 1.36 | 1.84 | 2.15 | 2.36 | |
| Free Cash Flow | 101.73 | 136.42 | 164.23 | 182.84 | |
| Capital Expenditures | (1.13) | (1.57) | (1.63) | (2.13) | |
| Piotroski F-Score | 7.00 | 7.00 | 7.00 | 7.00 | |
| Other line items | |||||
| Cash ROIC | 11.59% | 14.06% | 15.45% | 15.67% | |
| Accounts Receivable Turnover | 15.61 | 23.64 | 23.83 | 30.36 | |
| Accounts Payable Turnover | 10.31 | 38.20 | 6.11 | 8.01 | |
| Inventory Turnover | 2.13 | 1.91 | 1.69 | 1.44 | |
| Average Days of Payables | 30.08 | 9.53 | 110.50 | 52.91 | |
| Days of Inventory on Hand | 202.48 | 257.96 | 331.22 | 302.55 | |
| Tax Rate | (0.26) | (0.34) | (0.31) | (0.29) | |
| Research and Development Expense of Revenue | 16.30% | 14.29% | 13.93% | 15.12% | |
| Selling, General and Administrative Expense of Revenue | 30.11% | 28.97% | 28.37% | 27.46% | |
| Share Based Compensation of Revenue | 5.86% | 5.46% | 5.21% | 5.00% | |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating CF/Net income | 2.86 | 2.34 | 2.27 | 2.29 | |
| Depreciation/Fixed assets | 0.90 | 0.80 | 0.84 | 0.70 | |
| Capex/Depreciation | (0.76) | (1.01) | (0.97) | (1.19) | |
| Revenue per Share | 8.00 | 9.13 | 9.85 | 10.84 | |
| Operating CF per Share | 1.38 | 1.86 | 2.17 | 2.38 | |
| Capex per Share | (0.02) | (0.02) | (0.02) | (0.03) | |
| Capex to Sales | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Profit Margin | 6.01% | 8.71% | 9.69% | 9.59% |
Columns are period end dates